Showing results (121-130 of 259) with videos related to
Sort By:
Pageof 26
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 13, 2023
Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 TrialJames Chih-Hsin Yang, Geoffrey Liu, Shun Lu, et al.Cancers|January 16, 2021
Lysine Deprivation Induces AKT-AADAT Signaling and Overcomes EGFR-TKIs Resistance in <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer CellsChia-Chi Hsu, Albert Ying-Po Yang, Jui-Yi Chen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013
ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancerBruce E Johnson, Fairooz Kabbinavar, Louis Fehrenbacher, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2012
Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancerKang-Yi Su, Hsuan-Yu Chen, Ker-Chau Li, et al.Clinical Lung Cancer|December 3, 2014
Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinomaBin-Chi Liao, Yu-Yun Shao, Ho-Min Chen, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 27, 2014
Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populationsYen-Fu Chen, Min-Shu Hsieh, Shang-Gin Wu, et al.Cancer Letters|September 1, 2012
ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitorsCheng-Po Huang, Meng-Feng Tsai, Tzu-Hua Chang, et al.Lung Cancer (Amsterdam, Netherlands)|July 28, 2021
Real-world insights into patients with advanced NSCLC and MET alterationsMarisa Bittoni, James Chih-Hsin Yang, Jin-Yuan Shih, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 21, 2011
Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)Sumitra Thongprasert, Emma Duffield, Nagahiro Saijo, et al.JTO Clinical and Research Reports|October 17, 2022
Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With <i>ROS1</i>-Positive Advanced NSCLCYi-Long Wu, Shun Lu, James Chih-Hsin Yang, et al.Pageof 26